ES2136271T3 - Formulaciones de liposomas multilamerales que contienen un metabolito de acido araquidonico. - Google Patents

Formulaciones de liposomas multilamerales que contienen un metabolito de acido araquidonico.

Info

Publication number
ES2136271T3
ES2136271T3 ES95900532T ES95900532T ES2136271T3 ES 2136271 T3 ES2136271 T3 ES 2136271T3 ES 95900532 T ES95900532 T ES 95900532T ES 95900532 T ES95900532 T ES 95900532T ES 2136271 T3 ES2136271 T3 ES 2136271T3
Authority
ES
Spain
Prior art keywords
metabolite
formulations
multilameral
liposomes containing
prostaglandins
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES95900532T
Other languages
English (en)
Inventor
Robert P Lenk
Michelle L Tomsho
Robert L Suddith
Robert J Klimchak
Andrew S Janoff
Sharma R Minchey
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Elan Pharmaceuticals LLC
Original Assignee
Liposome Co Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Liposome Co Inc filed Critical Liposome Co Inc
Application granted granted Critical
Publication of ES2136271T3 publication Critical patent/ES2136271T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A61K9/1277—Preparation processes; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Dispersion Chemistry (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Vascular Medicine (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Manufacturing Of Micro-Capsules (AREA)
  • Saccharide Compounds (AREA)
  • Detergent Compositions (AREA)

Abstract

LA INVENCION SUMINISTRA UN LIPOSOMA MUTILAMELAR QUE CONTIENE UN METABOLITO DE ACIDO ARAQUIDONICO, DOS O MAS BICAPAS QUE CONTIENEN LIPIDOS Y DOS O MAS COMPARTIMENTOS ACUOSOS QUE CONTIENEN UN NEUTRALIZADOR INHIBIDOR DE LA LIBERACION. LOS METABOLITOS DEL ACIDO ARAQUIDONICO PREFERIDOS SON LAS PROSTAGLANDINAS, PARTICULARMENTE LA PGE1. LAS FORMULACIONES LIPOSOMIALES PUEDE UTILIZARSE PARA TRATAR ANIMALES, PARTICULARMENTE HUMANOS, DE ENFERMEDADES, DESORDENES O CONDICIONES QUE PUEDAN MEJORARSE MEDIANTE LA PROSTAGLANDINA, POR EJEMPLO, ENFERMEDADES CARACTERIZADAS POR LA ACTIVACION Y LA ADHESION CELULAR, INFLAMACION Y/O TOXEMIA.
ES95900532T 1993-11-04 1994-11-03 Formulaciones de liposomas multilamerales que contienen un metabolito de acido araquidonico. Expired - Lifetime ES2136271T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US14789893A 1993-11-04 1993-11-04
US15285293A 1993-11-16 1993-11-16
US18008994A 1994-01-11 1994-01-11

Publications (1)

Publication Number Publication Date
ES2136271T3 true ES2136271T3 (es) 1999-11-16

Family

ID=27386612

Family Applications (2)

Application Number Title Priority Date Filing Date
ES95900504T Expired - Lifetime ES2144118T3 (es) 1993-11-04 1994-11-03 Metodos de tratamiento que emplean formulaciones liposomicas unilamelares de metabolitos del acido araquidonico.
ES95900532T Expired - Lifetime ES2136271T3 (es) 1993-11-04 1994-11-03 Formulaciones de liposomas multilamerales que contienen un metabolito de acido araquidonico.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ES95900504T Expired - Lifetime ES2144118T3 (es) 1993-11-04 1994-11-03 Metodos de tratamiento que emplean formulaciones liposomicas unilamelares de metabolitos del acido araquidonico.

Country Status (13)

Country Link
EP (2) EP0726763B1 (es)
JP (2) JPH09504793A (es)
KR (2) KR100355246B1 (es)
AT (2) ATE191141T1 (es)
AU (2) AU687921B2 (es)
CA (2) CA2175896A1 (es)
DE (2) DE69423773T2 (es)
DK (2) DK0726763T3 (es)
ES (2) ES2144118T3 (es)
GR (2) GR3032006T3 (es)
NO (2) NO312809B1 (es)
PT (1) PT726763E (es)
WO (2) WO1995012388A1 (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2179986A1 (en) * 1994-01-11 1995-07-13 Andrew S. Janoff Treatment using arachidonic acid metabolite and particulate formulations
CA2260859A1 (en) * 1996-07-22 1998-01-29 Monsanto Company Thiol sulfone metalloprotease inhibitors
US6747027B1 (en) 1996-07-22 2004-06-08 Pharmacia Corporation Thiol sulfonamide metalloprotease inhibitors
US6362183B1 (en) 1997-03-04 2002-03-26 G. D. Searle & Company Aromatic sulfonyl alpha-hydroxy hydroxamic acid compounds
WO1998039316A1 (en) 1997-03-04 1998-09-11 Monsanto Company N-hydroxy 4-sulfonyl butanamide compounds
WO1998039315A1 (en) 1997-03-04 1998-09-11 Monsanto Company Aromatic sulfonyl alpha-cycloamino hydroxamic acid compounds
US20010039287A1 (en) 1997-11-14 2001-11-08 Thomas E Barta Aromatic sulfone hydroxamic acid metalloprotease inhibitor
US6750228B1 (en) 1997-11-14 2004-06-15 Pharmacia Corporation Aromatic sulfone hydroxamic acid metalloprotease inhibitor
JP2001523662A (ja) 1997-11-14 2001-11-27 ジー・ディー・サール・アンド・カンパニー 芳香族スルホンヒドロキサム酸メタロプロテアーゼ阻害剤
AP2001002240A0 (en) 1999-02-08 2001-09-30 Searle & Co Sufamato hydroxamic acid metalloprotease inhibitor.
US6583299B1 (en) 1999-05-20 2003-06-24 G.D. Searle & Co. α-amino-β-sulfonyl hydroxamic acid compounds
US6683078B2 (en) 2001-07-19 2004-01-27 Pharmacia Corporation Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
JP2003342196A (ja) * 2002-05-31 2003-12-03 Mukku:Kk 静脈注射用組成物、その製造法およびその製剤
WO2013039851A1 (en) 2011-09-12 2013-03-21 Mallinckrodt Llc Optical agents for imaging and visualization of matrix metalloproteinase enzymes
CN111053743B (zh) * 2018-10-16 2023-07-14 石药集团中奇制药技术（石家庄）有限公司 一种前列地尔脂质体及其制备方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988009170A1 (en) * 1987-05-22 1988-12-01 The Liposome Company, Inc. Prostaglandin-lipid formulations
US5262168A (en) * 1987-05-22 1993-11-16 The Liposome Company, Inc. Prostaglandin-lipid formulations
JPH0395118A (ja) * 1989-09-07 1991-04-19 Green Cross Corp:The プロスタグランジン含有脂肪小体製剤
JPH04356421A (ja) * 1991-03-06 1992-12-10 Green Cross Corp:The プロスタグランジン類含有脂肪小体組成物
ATE176401T1 (de) * 1991-05-07 1999-02-15 Liposome Co Inc Liposomale prostaglandinformulierungen
JPH05139977A (ja) * 1991-05-17 1993-06-08 Green Cross Corp:The プロスタグランジン類リポソーム複合体を充填した注射器

Also Published As

Publication number Publication date
DK0726763T3 (da) 2000-07-10
KR100355247B1 (ko) 2003-01-24
JPH09511216A (ja) 1997-11-11
NO312809B1 (no) 2002-07-08
KR100355246B1 (ko) 2003-01-06
NO961779L (no) 1996-05-02
DK0726764T3 (da) 1999-12-20
DE69423773D1 (de) 2000-05-04
EP0726763A1 (en) 1996-08-21
ATE184785T1 (de) 1999-10-15
NO312810B1 (no) 2002-07-08
EP0726764A1 (en) 1996-08-21
AU8130894A (en) 1995-05-23
KR960705543A (ko) 1996-11-08
NO961778L (no) 1996-06-25
CA2175896A1 (en) 1995-05-11
GR3033817T3 (en) 2000-10-31
AU687921B2 (en) 1998-03-05
DE69420859T2 (de) 2000-01-05
EP0726764B1 (en) 1999-09-22
ATE191141T1 (de) 2000-04-15
NO961778D0 (no) 1996-05-02
CA2175057A1 (en) 1995-05-11
DE69420859D1 (de) 1999-10-28
WO1995012389A1 (en) 1995-05-11
DE69423773T2 (de) 2000-07-20
KR960705544A (ko) 1996-11-08
WO1995012388A1 (en) 1995-05-11
ES2144118T3 (es) 2000-06-01
NO961779D0 (no) 1996-05-02
PT726763E (pt) 2000-09-29
EP0726763B1 (en) 2000-03-29
JPH09504793A (ja) 1997-05-13
GR3032006T3 (en) 2000-03-31
AU8132694A (en) 1995-05-23

Similar Documents

Publication Publication Date Title
DK0726764T3 (da) Multilamel-liposomale arachidonsyremetabolitformuleringer
ES2170335T3 (es) Estabilizacion de un retinoide inestable en emulsiones aceite en agua para composiciones para el cuidado de la piel.
MX9302244A (es) Composicion de gel acuoso de retinoides.
ES2178298T3 (es) Compuestos anti-inflamatorios.
AR023093A1 (es) Composiciones cosmeticas para la piel con contenido de dextrano y un acido carboxilico debil.
ES2133327T3 (es) Composiciones detergentes que contienen calcio y una amida polihidroxilica de acido graso.
NO973017L (no) Nye trienoiske retinoid forbindelser og fremgangsmåter
ES2180164T3 (es) Agentes acuosos para el cuidado de la piel y del cabello.
ES2111355T3 (es) Sal de l-carnitina y composiciones cosmeticas y farmaceuticas que la contienen para el tratamiento de dermatosis.
CA2203310A1 (fr) Comprime matriciel permettant la liberation prolongee du sel de sodium de tianeptine apres administration par voie orale
ATE297402T1 (de) Phospholipide mit ungesattigten alkyl- und acylketten
DK0729352T3 (da) Interdigiteringsfusionsliposomer indeholdende arachidonsyremetabolitter
MX9302419A (es) Derivados de acido tetronico, tiotetronico y tetramico.
ES2141978T3 (es) Retinoides triciclicos, metodos para su produccion y uso.
FI910308A0 (fi) Vattenloesliga vitamin a preparationer foer applicering pao huden.
PA8436301A1 (es) Compuestos de amonio cuaternario
ES2178762T3 (es) Empleo de esterolsufatos como productos activos para la fabricacion de agentes para inhibir las serinpro-teasas.
KR950700685A (ko) 최음제로서 사용되는 요드화수소산(use of hydriodic acid as an aphrodisiac)
MX9301626A (es) Procedimientos e intermediearios para la preparacion de benzaldehidos-2-substitiudos.
IT1265422B1 (it) Unguento farmaceutico privo di azione irritativa della pelle e procedimento per la sua preparazione
AR002576A1 (es) Mezclas fungicidas y un metodo para controlar hongos fitopatogenicos.
HN2001000121A (es) Combinacion de carboxialquileter- inhibidor cat
ITMI940953A0 (it) Butirrati e isomeri di propilenglicol monometiletere e procedimento per la loro preparazione

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 726764

Country of ref document: ES